RESUMEN
Forty dogs with canine leishmaniosis (CL) participated in this study, which was designed to investigate the effect of allopurinol on the progression of the renal lesions associated with this disease. The animals were allocated into 5 groups. Group A dogs (n = 12) had neither proteinuria nor renal insufficiency, group B dogs (n= 10) had asymptomatic proteinuria, and group C dogs (n = 8) were proteinuric and azotemic. Two more groups, CA and CB, comprising 5 dogs each, served as controls for groups A and B, respectively. Group A, B, and C dogs received allopurinol PO (10 mg/kg q12h) for 6 months, whereas group CA and CB dogs were placebo-treated. Serum biochemistry profile, urinalysis, urine protein/creatinine ratio, and glomerular filtration rate (GFR) measurements were carried out at the beginning of the study, the 3rd month, and the 6th month, whereas renal biopsies were carried out only at the beginning and the end of the trial. Membranoproliferative glomerulonephritis was the most common cause of chronic renal failure. Mesangioproliferative and tubulointerstitial nephritis were detected even in group A and CA dogs. Allopurinol not only lowered proteinuria in group B dogs but also prevented the deterioration of GFR and improved the tubulointerstitial, but not the glomerular, lesions in both group A and group B dogs. Further, it resolved the azotemia in 5 of the 8 dogs admitted with 2nd stage chronic renal failure (group C). Consequently, treatment with allopurinol is advisable in CL cases with asymptomatic proteinuria or 1st-2nd stage chronic renal failure.
Asunto(s)
Alopurinol/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Leishmaniasis Visceral/veterinaria , Nefritis/veterinaria , Animales , Enfermedad Crónica/tratamiento farmacológico , Perros , Inhibidores Enzimáticos/uso terapéutico , Femenino , Leishmaniasis Visceral/complicaciones , Leishmaniasis Visceral/tratamiento farmacológico , Masculino , Nefritis/complicaciones , Nefritis/tratamiento farmacológicoAsunto(s)
Antígenos de Grupos Sanguíneos , Gatos/sangre , Gatos/genética , Pigmentación , Animales , Femenino , Grecia , Cabello , Masculino , Linaje , Prevalencia , Factores SexualesAsunto(s)
Aerofagia/inducido químicamente , Aerofagia/veterinaria , Anestésicos Disociativos/efectos adversos , Ansiolíticos/efectos adversos , Enfermedades de los Perros/inducido químicamente , Dilatación Gástrica/inducido químicamente , Dilatación Gástrica/veterinaria , Tiletamina/efectos adversos , Zolazepam/efectos adversos , Anestésicos Disociativos/administración & dosificación , Animales , Ansiolíticos/administración & dosificación , Benzodiazepinas , Perros , Inyecciones Intramusculares , Masculino , Tiletamina/administración & dosificación , Zolazepam/administración & dosificaciónRESUMEN
The medical records of 158 dogs with visceral leishmaniasis confirmed cytologically and/or serologically were reviewed. Ages of affected dogs varied from nine months to 15 years, with a male-to-female ratio of 1.3. The most common clinical manifestations of the disease were variable cutaneous lesions such as exfoliative dermatitis and skin ulcerations, chronic renal failure, peripheral lymphadenopathy or lymph node hypoplasia, masticatory muscle atrophy (i.e., chronic myositis), ocular lesions (i.e., conjunctivitis, keratoconjunctivitis sicca, blepharitis, and uveitis), and poor body condition. Ascites, nephrotic syndrome, epistaxis, polyarthritis, and ulcerative stomatitis were seen only in a small number of cases. Clinical splenomegaly was not a common finding. The clinicopathological abnormalities were nonregenerative anemia, hyperproteinemia, glomerular proteinuria, and symptomatic or asymptomatic azotemia. In this study, an indirect immunofluorescence assay's diagnostic sensitivity was found to be higher than that of lymph node aspiration cytology.